At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Mr Richard Gonzalez performed for AbbVie in 2013.
2013 Liftstream Analysis: With the divestment of AbbVie from Abbott at the beginning of 2013, Mr Gonzalez has been chosen to lead the new enterprise. Mr Gonzalez has been tasked with developing the company and broadening the company’s portfolio beyond the commercial juggernaut which Humira is.
• Prove to investors there is life after Humira
• Advance AbbVie’s extensive pipeline of products
• Gel together the ‘new’ AbbVie workforce
2014 Liftstream Verdict: Abbvie’s first year last year after the Abbott Labs split, a break-up which seems to have worked out well so far. A strong year for AbbVie saw the stock rise 59% and a number of big partnering deals put in place. AbbVie signed multimillion dollar deals with European biotechs Galapagos and Ablynx as well as extending a deal with Seattle Genetics. Mr Gonzalez and AbbVie moved to show there could be life after Humira with positive data for AbbVie Hep C drug, positive data for Humira in alternate indications and impressive results for breast cancer drug Veliparib. The critical point in 2014 for AbbVie will be when they file their promising combination Hep C drug and what comes from that. With three companies hot on AbbVie’s tail can they successfully launch in the multibillion dollar Hep C market?
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email email@example.com or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.